男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Americas

US FDA authorizes second COVID-19 booster doses for vulnerable groups

Xinhua | Updated: 2022-03-30 10:35
Share
Share - WeChat
A sign at a drug store advertises the COVID-19 vaccine in New York City on Nov 19, 2021. [Photo/Agencies]

LOS ANGELES - The US Food and Drug Administration (FDA) on Tuesday authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.

A second booster dose of the Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine, said the FDA.

Meanwhile, the FDA authorized a second booster dose of the Pfizer-BioNTech COVID-19 vaccine to be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receiving a first booster dose, and a second booster dose of the Moderna COVID-19 vaccine be administered to individuals 18 years of age and older with the same certain kinds of immunocompromise.

The FDA has determined that the known and potential benefits of a second COVID-19 vaccine booster dose with either of these vaccines outweigh their known and potential risks in these populations.

"Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns," said the agency in a statement.

The FDA previously authorized a single booster dose for certain immunocompromised individuals following completion of a three-dose primary vaccination series. The new move has extended the availability of a second booster dose to other populations at higher risk for severe disease, hospitalization and death.

"Current evidence suggests some waning of protection over time against serious outcomes from COVID-19 in older and immunocompromised individuals. Based on an analysis of emerging data, a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine could help increase protection levels for these higher-risk individuals," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.

"Additionally, the data show that an initial booster dose is critical in helping to protect all adults from the potentially severe outcomes of COVID-19. So, those who have not received their initial booster dose are strongly encouraged to do so," he said.

The second booster for adults 50 and older and for people 12 and older who are immunocompromised is expected to become available immediately after the US Centers for Disease Control and Prevention reaches a decision on who should get it.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 湘阴县| 三台县| 平和县| 鹿邑县| 增城市| 丽江市| 冀州市| 仪陇县| 辽宁省| 水城县| 彭水| 宜丰县| 华容县| 章丘市| 安阳市| 宜章县| 元江| 乌兰县| 禹城市| 平乐县| 泸州市| 阿勒泰市| 黎城县| 屏边| 镇安县| 个旧市| 贺州市| 当阳市| 邹城市| 新郑市| 齐齐哈尔市| 清远市| 绩溪县| 佛学| 江北区| 高邮市| 尉犁县| 犍为县| 法库县| 禹州市| 房山区|